Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. MRNA led at +60.23% ($130.38 → $208.90), closing at 75.81% of its range — the only name in the report finishing near its highs — with a +30.33% period return. TEM (+54.35%) and EBS (+28.18%) followed, while KPTI anchored the bottom at -61.19% ($1.92 → $0.75), with QURE (-52.16%) and STIM (-34.77%) close behind.

Implied volatility consistently mispriced the move. TEM was the biggest surprise at 3.80x realized-vs-implied, with MRNA (3.42x) and SYK (3.28x) also far exceeding what options priced in. QURE's 174.63% realized vol against 73.05% implied (2.98x) was the starkest absolute gap. Conversely, the highest-IV names were the most overpriced: CDXS (350.78% IV, 0.26x), DBVT (292.38%, 0.31x), MGNX (0.64x) and HUM (77.93%, 0.77x) all realized far less than implied.

Range placement skewed sharply toward the lows. STIM closed at 2.65% of range, with DBVT (3.32%), QURE (4.18%), ANAB and KPTI (4.68%) and MGNX (5.52%) clustered at the bottom — a decisively weak close for the small-cap cohort.

Broader Market Context

Differential behavior within the sector. The 121-point spread between MRNA (+60.23%) and KPTI (-61.19%) is far wider than anything the broad market produced in a three-week window, and the split was structural rather than random. Large-cap pharma and sector proxies — XLV (+4.09%), ABBV (+9.17%), LLY (+9.14%), MRK (+7.90%), GILD (+7.88%) — moved in a tight, low-volatility band with realized vol between 12% and 26%. Small- and mid-cap biotech and devices moved in multiples of that: QURE realized 174.63% vol, KPTI 143.43%, STIM 70.45%. Managed care formed a third, distinctly negative cluster — UNH (-10.81%), ELV (-12.04%), HUM (-12.11%), CVS (-14.03%), CNC (-14.61%) — moving together in a way that looks more like a shared thematic repricing than independent stock stories.

Rotation vs. idiosyncratic risk. This does not read as a clean sector rotation. XLV's modest +4.09% change with a -1.27% period return suggests no decisive macro flow into or out of healthcare as a whole. Instead:

• The managed-care cohort's tight, uniform decline is consistent with a sub-industry-level repricing — the kind of move policy or reimbursement expectations tend to produce.
• The biotech tails (MRNA, TEM up; QURE, KPTI, DBVT, MGNX down) show realized-vs-implied ratios and near-extreme range closes typical of binary, stock-specific catalysts rather than beta.
• Large-cap pharma's low realized vol and slightly negative period returns look like defensive ballast, not leadership.

Plausible current drivers. Several themes could plausibly relate to what the numbers show, though none can be confirmed from this data alone. The managed-care weakness is consistent with ongoing scrutiny of utilization trends, Medicare Advantage rate assumptions, and exchange-subsidy policy debate. The biotech dispersion is consistent with a dense clinical and regulatory calendar, where the collapse in high-IV names (CDXS, DBVT, MGNX realizing far below implied) suggests options markets priced catalysts that largely resolved without a violent move. Rate expectations also matter disproportionately here: long-duration, pre-revenue biotech is unusually sensitive to discount-rate shifts, which likely amplified both tails.